This HTML5 document contains 141 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://dx.doi.org/10.1002/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q50558699
rdf:type
wikibase:Item
schema:description
مقالة علمية نشرت في أكتوبر 2010 vitenskapelig artikkel научни чланак article scientifique wetenschappelijk artikel מאמר מדעי 2010年学术文章 2010年學術文章 article scientific artigo científico vetenskaplig artikel articolo scientifico научна статия wissenschaftlicher Artikel 2010年の論文 наукова стаття, опублікована в жовтні 2010 2010年學術文章 naučni članak scientific article published in October 2010 artikull shkencor অক্টোবর ২০১০-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ artykuł naukowy บทความทางวิทยาศาสตร์ научни чланак 2010年学术文章 2010年學術文章 videnskabelig artikel vědecký článek 2010年學術文章 artigo científico 2010年学术文章 научная статья articol științific επιστημονικό άρθρο 2010年学术文章 scientific article published in October 2010 სამეცნიერო სტატია artikulong pang-agham bilimsel makale vedecký článok tieteellinen artikkeli artikel ilmiah vitskapeleg artikkel 2010年学术文章 мақолаи илмӣ tudományos cikk 2010年學術文章 bài báo khoa học artículo científico publicado en 2010 2010年学术文章 scienca artikolo 2010년 논문 2010 nî lūn-bûn scientific article published in October 2010 artigo científico teaduslik artikkel article científic artículu científicu
p:P577
wds:Q50558699-826DB160-D7C3-4911-99BE-36B902C1585D
wdt:P577
2010-10-01T00:00:00Z
p:P407
wds:Q50558699-E76E6B81-3E3E-4B88-B6B2-982CDB36265C
wdt:P407
wd:Q1860
p:P2860
wds:Q50558699-A89DC609-4AE2-4EB5-BD9E-0CE245BA1E74 wds:Q50558699-AEBB9C7F-D960-4393-86E6-D09DBA2F806B wds:Q50558699-C9F80421-C10A-43C0-A3CB-883BC3549804 wds:Q50558699-9B1DC2F7-26A7-4F43-82CA-24CE94E651E0 wds:Q50558699-9B840789-ABB2-41C2-B620-485907C11784 wds:Q50558699-A47DBFAF-9A0C-44B3-8E21-109908B2ABF9 wds:Q50558699-FC219B32-7464-4E6C-B737-6DEA19B49339 wds:Q50558699-D1B44555-B266-4F16-967D-BEF22A83C3F6 wds:Q50558699-D934A21C-4867-441F-956B-B0043D9BAB7C wds:Q50558699-2D1F83C8-AD45-497A-A995-3E8756E1D7F8 wds:Q50558699-3C779B75-D77A-4C36-BA8E-841551357C1D wds:Q50558699-3CA34DBA-F4CE-46C5-941C-6131830FE1F5 wds:Q50558699-42ED210F-B1C6-4C2B-81BC-A6E335982EE0 wds:Q50558699-2397F071-E74D-4228-BCF7-5B2EBE5EB16A wds:Q50558699-29B88151-D714-4595-9587-6D7C75488686 wds:Q50558699-72CC28A3-A654-4C6B-806E-FC53C6B96545 wds:Q50558699-80ABF4A0-9534-43B7-B4D0-96C0ACDCF419 wds:Q50558699-71B32BD0-8607-42B2-98A8-D4B48B7DE0C5 wds:Q50558699-1425E0E9-FE68-4A57-A249-F89505C6C295 wds:Q50558699-1E7A7BD1-5058-4FD6-9DB2-D3ADEDC21819
wdt:P2860
wd:Q50583960 wd:Q27860901 wd:Q36071289 wd:Q50561780 wd:Q38876960 wd:Q43970118 wd:Q29547886 wd:Q73154499 wd:Q55061788 wd:Q43035294 wd:Q40848439 wd:Q29614459 wd:Q56879398 wd:Q46122164 wd:Q50564459 wd:Q27860949 wd:Q40587923 wd:Q73032290 wd:Q33364130 wd:Q43040369
p:P2093
wds:Q50558699-00D5B5A9-C3B6-458C-9583-DF8DE71A49AA wds:Q50558699-6618D702-7C81-4803-A576-A23D1819D473 wds:Q50558699-776A7CA7-F293-4EDE-BD27-D9D3F830D757
wdt:P2093
Robert J de Knegt Harry L A Janssen Robert Roomer
rdfs:label
Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.
skos:prefLabel
Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.
schema:name
Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.
p:P50
wds:Q50558699-2916482D-E573-479E-B7FD-F9DE7620CEDF
wdt:P50
wd:Q40007319
p:P1476
wds:Q50558699-8761893B-7D75-4707-B3E5-3D889FB4FFAD
wdt:P1476
Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.
p:P304
wds:Q50558699-2846BD04-B62E-48B5-9B83-542C7E2B1378
wdt:P304
1225-1231
p:P31
wds:Q50558699-A8EA3E0F-348F-4A91-9494-B91E7BE1052D
wdt:P31
wd:Q13442814
p:P921
wds:Q50558699-D5B74D0C-BDC1-4850-B2DC-BB9E9D49A221 wds:Q50558699-6E409FE3-A094-49C7-95E8-C7C54D99743F
wdt:P921
wd:Q62019625 wd:Q421862
p:P698
wds:Q50558699-05814858-4FDF-4D61-9811-4AA4966F8580
wdtn:P698
n10:20830784
wdt:P698
20830784
p:P1433
wds:Q50558699-11145231-626F-4D6E-A96E-4E1158FB05AF
wdt:P1433
wd:Q15724398
p:P433
wds:Q50558699-DEF9A918-5D63-4F82-8469-FD0BC96860D1
p:P478
wds:Q50558699-CF0619AC-C086-4FE2-A5BC-CCD70AAEBA9E
wdt:P433
4
wdt:P478
52
p:P356
wds:Q50558699-E0963D8F-9C88-4BDD-AFE7-921BDCF74F03
wdtn:P356
n11:HEP.23842
wdt:P356
10.1002/HEP.23842
p:P5875
wds:Q50558699-650B84F4-A2E0-4125-94D1-9AC1FF7E783E
wdt:P5875
46192803